Side-by-side · Research reference
GHRP-2vsPancragen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED15/42 cited
BAnimal-StrongHUMAN-REVIEWED23/39 cited
GHRP-2
Hexapeptide GHRP · Phase 2 (clinical diagnostic)
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
GHRP-2
Pancragen
Primary target
Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Downstream effect
Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Feedback intact?
Yes, with somatostatin feedback active
Yes — preserves physiological glucose-insulin response
Origin
Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-2
Pancragen
Lower / starter dose
50 mcg per dose
—
Evidence basis
Phase 2 + clinical diagnostic useBowers 1990
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Duration
8–12 weeks on / 4 off (anecdotal)
—
Reconstitution
Bacteriostatic water
—
Timing
Pre-sleep + fasted preferred
—
Primate dose (rhesus macaque)
—
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
Diabetes model
—
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
04Side Effects & Safety
Parameter
GHRP-2
Pancragen
Prolactin elevation
Mild but measurable
—
Hunger
Strong appetite increase
—
Injection site reaction
Mild erythema
—
IGF-1 elevation
Strong; monitor with chronic high-dose use
—
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
—
Reported adverse events
—
None documented in primate studies
Human safety data
—
No published human trials; clinical use limited to Russian gerontology protocols
Absolute Contraindications
GHRP-2
- ·Active malignancy
- ·Pregnancy / breastfeeding
Pancragen
—Relative Contraindications
GHRP-2
- ·Untreated diabetes
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
05Administration Protocol
Parameter
GHRP-2
Pancragen
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
2. Injection site
SQ — abdomen or thigh. Rotate sites.
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
3. Timing
Pre-sleep + fasted preferred.
No specific timing constraints documented. Administered once daily in primate protocols.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
5. Needle
29–31G, 4–8 mm insulin syringe.
—
06Stack Synergy
GHRP-2
+ CJC-1295 (no DAC)
StrongGHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.
- GHRP-2
- 100–200 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- High-amplitude GH pulse, body composition
Pancragen
— no documented stacks